Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR

On February 2, Asia Hong announced that it has reached a cooperation with ReviR Brook Technology (hereinafter referred to as "ReviR"), a biotechnology company dedicated to the development of RNA-targeted small molecule drugs in the field of oncology and hereditary diseases, to jointly carry out innovative therapeutic research on genitourinary tumors and related major diseases by using ReviR's self-developed AI drug discovery platform and targeted RNA technology.

The cooperation involves multiple tumor targets, and it is expected that the cooperation between the two parties will improve the prognosis of patients and promote the treatment of related diseases. Under the agreement, Rainbow will leverage ReviR's innovative RNA regulatory technologies, BindeR and SpliceR, to identify and develop innovative therapies that target RNA for oncology treatment.

As an innovative biotechnology company, ReviR combines AI computing with high-throughput drug discovery technology to bring the next generation of innovative drug therapies to patients. With its VoyageR AI drug discovery platform, ReviR uses computing to empower traditional pharmaceutical methods and advance breakthroughs in the undruggable problem at the RNA level, and its research and development focus is currently focused on the central nervous system, tumors and other genetic diseases.

Dr. Paul August, Chief Scientific Officer of ReviR, said, "In the field of genitourinary oncology, Ahong's pharmaceutical company is an international leader, and we look forward to working with Ahongs to develop new therapies and new breakthroughs for tumor indications." ReviR's BindeR and SpliceR platforms are uniquely positioned to advance the development of undruggable tumor-targeted therapies, and it is believed that this collaboration will accelerate the progress of novel therapies. ”

Dr. Peng Yue, CEO of ReviR, said, "This collaboration with Yahong will bring more expertise, technology and resources to ReviR to quickly validate the effectiveness of our RNA-targeting small molecule drug discovery platform. More importantly, the cooperation provides an opportunity for the ReviR team to develop synergistically with Asiahong's senior and professional expert team, and the strong combination of the two teams will undoubtedly seek innovative development and greater breakthroughs in the field of targeted RNA and small molecule drug discovery. As the first addition to ReviR's many upcoming collaborations, we believe this collaboration will greatly enhance our ability to improve patient outcomes and advance into more areas of oncology research." ”

Dr. Yu Chen, Vice President of Biological Research and Head of Translational Medicine Research, Department of New Drug Discovery, said Dr. Yu Chen "We are pleased to partner with ReviR, an innovative biotechnology company focused on the development of targeted RNA small molecule therapeutics. We believe that our expertise in the development of small molecule anti-tumor drugs, combined with ReviR's innovative RNA regulation technology, will benefit more patients as soon as possible." We will continue to maintain a differentiated R&D strategy, focus on genitourinary tumors and related diseases, expand our global innovation impact, and provide innovative drugs to patients in China and around the world." ”

About ReviR Therapeutics

ReviR Therapeutics is an emerging biopharmaceutical company that develops RNA small molecule drugs for tumors and hereditary diseases. Founded in 2021, the company has set up dual headquarters in California and Shenzhen, China, and its core team members are deeply engaged in the fields of computational biology, AI, RNA biology and drug discovery. The team uses its cutting-edge technology and AI drug discovery platform VoyageR to conduct targeted RNA therapy research to develop more effective and safe disease-modifying therapies. ReviR currently focuses on using the three major mechanisms of BindeR, SpliceR and DegradeR to regulate RNA function against RNA targets, challenge "undruggable" targets, and meet the long-term unmet clinical needs of tumors and hereditary diseases. For more information, please visit the www.revirtx.com or email info@revirtx.com for an enquiry.

About Ahong

Asia Hong Pharma (stock code: 688176. Founded in March 2010, SH) is a global innovative pharmaceutical company focusing on genitourinary tumors and other major diseases. Adhering to the corporate mission of "improving human health and making life more dignified", Asia Hong Pharma aspires to become an international leading pharmaceutical company integrating R&D, production and commercialization in the field of focused treatment, providing the best integrated diagnosis and treatment solutions for patients in China and around the world.

The company adheres to innovative technologies and products as the core driving force, and deeply explores the mechanism of drug action by building its own R&D platform and core technology, and efficiently screens and evaluates drug candidates. Through its well-established R&D system and global drug development experience and expertise, Aqua is committed to launching first-in-class drugs and other innovative drugs with huge unmet therapeutic needs in focused therapeutic areas.

At the same time, through independent research and development and strategic cooperation, Asia Hong Pharma focuses on the in-depth layout of its product pipeline around genitourinary diseases, pays close attention to the technological frontier and treatment development trends in this field, insights and excavates unmet clinical needs, forward-looking product planning and life cycle management, and creates a superior product portfolio covering disease diagnosis to treatment, so as to benefit more Chinese and global patients.